BrightPath Bio and Cellistic Announce Collaboration for Phase 1 BCMA CAR-iNKT Cell Trial
BrightPath Bio (Tokyo Stock Exchange Growth 4594), a leader in iPS cell-derived Natural Killer T (NKT) cell therapy, and Cellistic, a pioneer in advanced iPS cell therapy manufacturing, have announced a new agreement focused on process development and manufacturing. The…